Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors. (Record no. 30131668)
[ view plain ]
000 -LEADER | |
---|---|
fixed length control field | 02283 a2200661 4500 |
005 - DATE AND TIME OF LATEST TRANSACTION | |
control field | 20250518061806.0 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
fixed length control field | 202006s 0 0 eng d |
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
International Standard Serial Number | 1476-5594 |
024 7# - OTHER STANDARD IDENTIFIER | |
Standard number or code | 10.1038/s41388-019-1012-2 |
Source of number or code | doi |
040 ## - CATALOGING SOURCE | |
Original cataloging agency | NLM |
Language of cataloging | eng |
Transcribing agency | NLM |
100 1# - MAIN ENTRY--PERSONAL NAME | |
Personal name | O'Connor, Caitlin M |
264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
Date of production, publication, distribution, manufacture, or copyright notice | 20200619 |
245 00 - TITLE STATEMENT | |
Title | Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors. |
Medium | [electronic resource] |
260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
Name of publisher, distributor, etc. | Oncogene |
Date of publication, distribution, etc. | 01 2020 |
300 ## - PHYSICAL DESCRIPTION | |
Extent | 703-717 p. |
Other physical details | digital |
500 ## - GENERAL NOTE | |
General note | Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Amino Acid Substitution |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Arginine |
General subdivision | genetics |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Calmodulin-Binding Proteins |
General subdivision | metabolism |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Carcinogenesis |
General subdivision | drug effects |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Cell Line, Tumor |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Drug Resistance, Neoplasm |
General subdivision | genetics |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Humans |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | MAP Kinase Signaling System |
General subdivision | drug effects |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Membrane Proteins |
General subdivision | metabolism |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Mitogen-Activated Protein Kinase Kinases |
General subdivision | antagonists & inhibitors |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Molecular Dynamics Simulation |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Mutagenesis, Site-Directed |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Mutation |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Neoplasms |
General subdivision | drug therapy |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Nerve Tissue Proteins |
General subdivision | metabolism |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Protein Kinase Inhibitors |
General subdivision | pharmacology |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Protein Phosphatase 2 |
General subdivision | genetics |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Recombinant Proteins |
General subdivision | genetics |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Transfection |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Tyrosine |
General subdivision | genetics |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Xenograft Model Antitumor Assays |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Leonard, Daniel |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Wiredja, Danica |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Avelar, Rita A |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Wang, Zhizhi |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Schlatzer, Daniela |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Bryson, Benjamin |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Tokala, Eesha |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Taylor, Sarah E |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Upadhyay, Aditya |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Sangodkar, Jaya |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Gingras, Anne-Claude |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Westermarck, Jukka |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Xu, Wenqing |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | DiFeo, Analisa |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Brautigan, David L |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Haider, Shozeb |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Jackson, Mark |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Narla, Goutham |
773 0# - HOST ITEM ENTRY | |
Title | Oncogene |
Related parts | vol. 39 |
-- | no. 3 |
-- | p. 703-717 |
856 40 - ELECTRONIC LOCATION AND ACCESS | |
Uniform Resource Identifier | <a href="https://doi.org/10.1038/s41388-019-1012-2">https://doi.org/10.1038/s41388-019-1012-2</a> |
Public note | Available from publisher's website |
No items available.